Functional and Physical Interaction between p53 and BZLF1: Implications for Epstein-Barr Virus Latency

REFERENCES

• Agoff, S. N., J. Hou, D. Linzer, and B. Wu. 1993. Regulation of the human hsp70 promoter by p53. Science 259:84–87.
   PubMed Web of Science ®Google Scholar
• Baker, S., S. Markowitz, E. Fearon, J. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915.
   PubMed Web of Science ®Google Scholar
• Bargonetti, J., P. Friedman, S. Kern, B. Vogelstein, and C. Prives. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091.
   PubMed Web of Science ®Google Scholar
• Borellini, F., and R. Glazer. 1993. Induction of Spl-p53 DNA- binding heterocomplexes during granulocyte/macrophage colonystimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J. Biol. Chem. 268:7923–7928.
   PubMedGoogle Scholar
• Chang, Y., D. Dong, G. Hayward, and S. D. Hayward. 1990. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol. 64:3358–3369.
   PubMed Web of Science ®Google Scholar
• Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J. 5:3243–3249.
   PubMed Web of Science ®Google Scholar
• Cochet, C., D. Martel-Renoir, V. Grunewald, J. Bosq, G. Cochet, G. Schwaab, J.-F. Bemaudin, and I. Joab. 1993. Expression of the Epstein-Barr virus immediate-early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:358–365.
   PubMed Web of Science ®Google Scholar
• Cox, M., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313–321.
   PubMedGoogle Scholar
• Effert, P., R. McCoy, M. Abdel-Hamid, K. Flynn, Q. Zhang, P. Busson, T. Tursz, E. Liu, and N. Raab-Traub. 1992. Alterations of the p53 gene in nasopharyngeal carcinoma. J. Virol. 66:3768–3775.
   PubMed Web of Science ®Google Scholar
• Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358:83–86.
   PubMed Web of Science ®Google Scholar
• Farrell, P., G. Allen, F. Shanahan, K. Vousden, and T. Crook. 1991. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:2879–2887.
   PubMed Web of Science ®Google Scholar
• Farrell, P., D. Rowe, C. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus BZLF1 trans-activator specifically binds to consensus Apl site and is related to c-fos. EMBO J. 8:127–132.
   PubMed Web of Science ®Google Scholar
• Fixman, E., G. Hayward, and S. D. Hayward. 1992. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66:5030–5039.
   PubMed Web of Science ®Google Scholar
• Flemington, E., and S. Speck. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227–1232.
   PubMedGoogle Scholar
• Flemington, E., and S. Speck. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217–1216.
   PubMed Web of Science ®Google Scholar
• Funk, W., D. Pak, R. Karas, W. Wright, and J. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866–2871.
   PubMed Web of Science ®Google Scholar
• Furnari, F. B., V. Zacny, E. B. Quinlivan, S. Kenney, and J. S. Pagano. 1994. RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J. Virol. 68:1827–1836.
   PubMedGoogle Scholar
• Gaidano, G., P. Ballerini, J. Gong, G. Inghirami, A. Neri, E. Newcomb, I. Magrath, D. Knowles, and R. Dalla-Favera. 1991. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88:5413–5417.
   PubMed Web of Science ®Google Scholar
• Gannon, J., and D. Lane. 1987. p53 and DNA polymerase a compete for binding to SV40 T antigen. Nature (London) 329:456–458.
   PubMed Web of Science ®Google Scholar
• Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979–9983.
   PubMed Web of Science ®Google Scholar
• Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044–1051.
   PubMed Web of Science ®Google Scholar
• Gruffat, H., E. Manet, A. Rigolet, and A. Sergeant. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence specific DNA binding protein. Nucleic Acids Res. 18:6835–6843.
   PubMedGoogle Scholar
• Gutsch, D. E., E. A. Holley-Guthrie, Q. Zhang, B. Stein, M. A. Blanar, A. S. Baldwin, and S. C. Kenney. 1994. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kB. Mol. Cell. Biol. 14:1939–1948.
   PubMedGoogle Scholar
• Hardwick, J. M., S. Lazarowits, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274–2284.
   PubMedGoogle Scholar
• Holley-Guthrie, E., E. Quinlivan, E. Mar, and S. Kenney. 1990. The Epstein-Barr virus promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753–3759.
   PubMedGoogle Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. Harris. 1991. p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Hupp, T., D. Meek, C. Midgley, and D. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875–886.
   PubMed Web of Science ®Google Scholar
• Katz, D., R. Baumann, R. Sun, J. Kolman, N. Taylor, and G. Miller. 1992. Viral proteins associated with the Epstein-Barr virus transactivator, ZEBRA. Proc. Natl. Acad. Sci. USA 89:378–382.
   PubMedGoogle Scholar
• Kenney, S., J. Kamine, E. Holley-Guthrie, J. Lin, E. Mar, and J. Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729–1736.
   PubMedGoogle Scholar
• Kenney, S., E. Holley-Guthrie, E. Quinlivan, D. Gutsch, T. Bender, J. Giot, and A. Sergeant. 1992. The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol. Cell. Biol. 12:136–146.
   PubMedGoogle Scholar
• Kern, S., K. Kinzler, S. Baker, J. Nigro, V. Rotter, A. Levine, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711.
   PubMed Web of Science ®Google Scholar
• Kern, S., J. Pietenpol, S. Thiagalingam, A. Seymour, K. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53- regulated gene expression. Science 256:827–830.
   PubMed Web of Science ®Google Scholar
• Kieff, E., and D. Leibowitz. 1990. Epstein-Barr virus and its replication, p. 1889–1920. In B. Fields, and D. Knipe (ed.), Fields virology, 2nd ed., Raven Press, New York.
   Google Scholar
• Kouzarides, T., G. Packham, A. Cook, and P. Farrell. 1991. The BZLF1 protein of EBV has a coiled coil dimerization domain without a hepted leucine repeat but homology to the C/EBP leucine zipper. Oncogene 6:195–204.
   PubMedGoogle Scholar
• Lane, D., and L. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (London) 278:261–263.
   PubMed Web of Science ®Google Scholar
• Lechner, M., D. Mack, A. Finicle, T. Crook, K. Vousden, and L. Laimins. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045–3052.
   PubMed Web of Science ®Google Scholar
• Levine, A. 1990. p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419–426.
   PubMedGoogle Scholar
• Levine, A., J. Momand, and C. Finlay. 1991. The p53 tumor suppressor gene. Nature (London) 351:453–456.
   PubMed Web of Science ®Google Scholar
• Lieberman, P., and A. Berk. 1990. In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein- Barr virus Zta protein. J. Virol. 64:2560–2568.
   PubMed Web of Science ®Google Scholar
• Lieberman, P., and A. Berk. 1991. The Zta transactivator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 5:2441–2454.
   PubMedGoogle Scholar
• Luka, J., B. Kallin, and G. Klein. 1979. Induction of the Epstein-Barr virus cycle in latently infected cells by n-butyrate. Virology 94:228–231.
   PubMed Web of Science ®Google Scholar
• Maheswaran, S., S. Park, A. Bernard, J. Morris, F. Rauscher, D. Hill, and D. Haber. 1993. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5100–5104.
   PubMed Web of Science ®Google Scholar
• Manet, E., H. Gruffat, M. C. Trescol-Biemont, I. Moreno, P. Chambard, J. F. Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNA's generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819–1826.
   PubMedGoogle Scholar
• Miller, G. 1990. The Epstein-Barr virus, p. 1291–1957. In B. Fields, D. Knipe et al. (ed.), Fields virology. Raven Press, New York.
   Google Scholar
• Moar, M., R. Ber, G. Klein, A. Westman, and I. Eriksson. 1978. Somatic cell hybrids between human lymphoma cell lines. V. IdUrd inducibility and P3HR-1 superinfectability of DAUDI/ HeLa (DAD) and DAUDI/P3HR-1 (DIP-1) cell lines. Int. J. Cancer 22:669–674.
   PubMedGoogle Scholar
• Pallesen, G., S. Hamilton-Dutoit, M. Rowe, I. Lisse, E. Ralfkiaer, K. Sandvej, and L. Young. 1990. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J. Pathol. 165:289–299.
   Google Scholar
• Pallesen, G., K. Sandvej, S. Hamilton-Dutoit, M. Rowe, and L. Young. 1991. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 78:1162–1165.
   PubMed Web of Science ®Google Scholar
• Prives, C., and J. Manfredi. 1993. The p53 tumor suppressor protein: meeting review. Genes Dev. 7:529–534.
   PubMed Web of Science ®Google Scholar
• Quinlivan, E., E. Holley-Guthrie, M. Norris, D. Gutsch, S. Bachenheimer, and S. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus promoter, BMRF1. Nucleic Acids Res. 21:1999–2007.
   PubMedGoogle Scholar
• Raab-Traub, N. Personal communication.
   Google Scholar
• Raab-Traub, N., and K. Flynn. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47:883–889.
   PubMed Web of Science ®Google Scholar
• Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 antioncogene. Science 249:1049–1051.
   PubMed Web of Science ®Google Scholar
• Rooney, C., N. Taylor, J. Countryman, H. Jenson, J. Kolman, and G. Miller. 1988. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA 85:9801–9805.
   PubMedGoogle Scholar
• Sarnow, P., Y. Ho, J. Williams, and A. Levine. 1982. Adenovirus Elb-58 kd tumor antigen and SV40 large T antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387–394.
   PubMed Web of Science ®Google Scholar
• Scheffner, M., B. Werness, J. Huibregtse, A. Levine, and P. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136.
   PubMed Web of Science ®Google Scholar
• Schepers, A., D. Pich, and W. Hammerschmidt. 1993. A transcription factor with homology to the Apl family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J. 12:3921–3929.
   PubMed Web of Science ®Google Scholar
• Seto, E., A. Usheva, G. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028–12032.
   PubMed Web of Science ®Google Scholar
• Shaulian, E., A. Zauberman, D. Ginsgerg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581–5592.
   PubMed Web of Science ®Google Scholar
• Shimizu, N., and K. Takada. 1993. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence. J. Virol. 67:3240–3245.
   PubMedGoogle Scholar
• Sista, N., J. Pagano, W. Liao, and S. Kenney. 1993. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. USA 90:3894–3898.
   PubMedGoogle Scholar
• Smith, D., and K. Johnson. 1987. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31–40.
   Google Scholar
• Szekely, L., G. Selivanova, K. Magnusson, G. Klein, and K. Wimon. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5455–5459.
   PubMed Web of Science ®Google Scholar
• Takada, K., N. Shimuzu, S. Sakuma, and A. Keating. 1986. Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV BamHI Z DNA fragment. J. Virol. 57:1011–1022.
   Google Scholar
• Ullrich, S., C. Anderson, W. E. Mercer, and E. Appella. 1992. The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem. 267:15259–15262.
   PubMed Web of Science ®Google Scholar
• Urier, G., M. Buisson, P. Chambar, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including Apl binding sites. EMBO J. 8:1447–1453.
   PubMedGoogle Scholar
• Vogelstein, B., and K. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Vousden, K., T. Crook, and P. Farrell. 1993. Biological activities of p53 mutants in Burkitt's lymphoma cells. J. Gen. Virol. 74:803–810.
   PubMedGoogle Scholar
• Wang, E., P. Friedman, and C. Prives. 1989. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57:379–392.
   PubMed Web of Science ®Google Scholar
• Werness, B., A. Levine, and P. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79.
   PubMed Web of Science ®Google Scholar
• Whyte, P., N. Williamson, and E. Harlow. 1989. Cellular targets for transformation by the adenovirus E1A proteins. Cell 56:67–75.
   PubMed Web of Science ®Google Scholar
• Wilcock, D., and D. Lane. 1991. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (London) 349:429–431.
   PubMedGoogle Scholar
• Wiman, K., K. Magnusson, T. Ramgvist, and G. Klein. 1991. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633–1639.
   PubMed Web of Science ®Google Scholar
• Yew, P., and A. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357:82–85.
   PubMed Web of Science ®Google Scholar
• Young, L., R. Lau, M. Rowe, G. Niedobitek, G. Packham, F. Shanahan, D. Rowe, D. Greenspan, J. Greenspan, A. Rickinson, and P. Farrell. 1991. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator in oral hairy leukoplakia. J. Virol. 65:2868–2874.
   PubMed Web of Science ®Google Scholar
• Zalani, S., E. Holley-Guthrie, D. Gutsch, and S. Kenney. 1992. The Epstein-Barr virus immediate-early promoter, BRLF1, can be activated by the cellular Spl transcription factor. J. Virol. 66:7282–7292.
   PubMedGoogle Scholar
• Zur Hausen, H., G. Bornkamm, R. Schmidt, and E. Hecker. 1979. Tumor initiators and promoters in the induction of Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 76:782–785.
   PubMed Web of Science ®Google Scholar